PerAGraft GmbH

PerAGraft is dedicated to designing and producing patient individualised implants for cardiovascular applications in a fraction of time.


  • Founded: 01.08.2019
  • Address: Jülicher Straße 72a
  • Zip/Postcode: 52070
  • City: Aachen
  • Country: Germany
  • Mail:
  • Phone: +492418085872
  • Contact person for business: Dr. Valentine Gesché
  • Contact person for science: Dr. Kathrin Kurtenbach,

Company summary

PerAGraft aims to develop, produce and sell patient individualised implants for cardiovascular applications. The combination of an end-to-end digital process chain and an innovative textile manufacturing technology enable for the first time a fast realisation of textile-based individualised implants. PerAGraft was founded to define a new era in the treatment of complex aortic aneurysms and defining a new standard of care.

Technology field

Medical Technology – Patient individualised implants

Technology and USP

PerAGraft’s unique combination of an end-to-end digital process chain and an innovative textile manufacturing technology offer a number of advantages and benefits: its speed, a high variability in implant design, thus widening the treatable patient cohort, as well as a scalable and reliable industrial manufacturing process for a lot size 1.
Thus, for our first product, a patient individualised stent graft to treat complex aortic aneurysms, we are the only company on the market to create and deliver a customised implant in only 5 days. We have two patents pending and three more in preparation this year to secure our expeditious custom-made implant availability. By reducing design and manufacturing time, we believe to achieve a significant impact for the health care system, making the procedure more cost-effective throughout the hospital and patient economy. We intend to use PerAGrafting to conquer further applications such as e.g. heart valves. We save time. Save money. Save lives.

Development until now

We started the underlying research at RWTH Aachen University in 2011. In 2015 and 2018, we were able to obtain the proof of principle for our product. We have carried out a preclinical trial of 3 ½ months in the ovine model with outstanding results: we were able to prove the perfect fit and alignment of our implants. Further, we observed a promising cell ingrowth in the anchoring zones of the device.
Since 2018, we are funded by an EXIST Forschungstransfer project with almost 1 Mio. €. We founded the company in August 2019. Further, we received the innovation award of the State of North Rhine-Westphalia in the category “talent”. The innovation award of the state of North Rhine-Westphalia is, after the Future Prize awarded by the Federal President, the highest endowed award of its kind in Germany.
The next milestones are reaching the design freeze of our product and validating the both the product and the associated processes. Further, we want to set up the production site this year. We will also implement the quality management system by the end of the year.

Capital requirements:

We are currently seeking EUR 3 million for our first financing round. The goal is to complete the preclinical phase of our product, which will be followed by a first in man trial. During the funding period of 18 months, we want to acquire and establish the infrastructure for production (machinery, clean room and testing equipment), expand the team with complementary skills such as a textile machine operator and a software developer. In order to achieve our goals, we are seeking strong equity partners experienced in the medical technology industry and in finance.


Valentine Gesche

Dr. Valentine Gesché is the CEO of the company. She laid the foundation for the business idea of patient-individualized stent grafts in 2011 and completed her doctorate in this field in 2016. During her time at the Institute of Textile Technology of RWTH Aachen University, she was responsible for setting up the production for the manufacture of textile semi-finished products for a medical device including the establishment of a quality management system. From 2015-2017 she headed the Biohybrid & Medical Textiles division with 15 employees. She was responsible for the strategic orientation of the division as well as for financing and controlling. Due to her expertise, she has been a founding member and active member of the VDI guideline committee 5705 “Digital process chains in industrial medical technology” since 2016.

Alexander Loewen

Alexander Löwen successfully completed his master’s degree in general mechanical engineering with a specialisation in medical technology at RWTH Aachen University in 2015. Since December 2015 he is working as a research assistant at the Institute of Textile Technology at RWTH Aachen University in the field of medical implants. As a student research assistant, Mr. Löwen has been actively involved in the development of the current PerAGraft manufacturing process for patient-individualized stent grafts since 2012. Within the company he is responsible for the development and implementation of the individual process steps into the digital process chain, which includes in particular the interface to the physicians within the planning process and the data translation of the medical image data sets into the necessary machine data.

Kathrin Kurtenbach

Dr. Kathrin Kurtenbach completed her doctorate in 2016 in the field of wire-based and biohybrid implants at the Institute of Textile Technology of RWTH Aachen University. Her acquired expertise in the field of stent development is crucial for the design and layout of the PerAGraft stent graft. In her positions as deputy head of department and positions as head of two research groups (2015-2017), she was responsible for managing interdisciplinary and cross-departmental tasks. After her time at the institute she moved to the industry in 2018 as a product manager. However, she decided to give up her position for the purpose of founding her own company. In the PerAGraft company, she is the CTO and heads the research and development. Her many years of experience in project management within large EU consortia also predestine her for the responsibility of project management in the PerAGraft team.